Sign in

You're signed outSign in or to get full access.

Henry Toledo

Chief People Officer at MODV
Executive

About Henry Toledo

Henry Toledo, age 53, is ModivCare’s Chief People Officer, appointed effective August 28, 2023. He brings 30+ years across HR, operations, and strategy, previously serving as Chief People Officer at Valet Living, Global Head of Learning, Talent & Performance Operations at Citigroup, and Division VP/GM of ADP’s Recruiting Technology business; earlier HR roles at WellCare Health Plans and Aramark, with a master’s in management (Temple University), B.S. in HR management (Georgia State), UC Berkeley Haas AI: Business Strategy certificate, and Wharton Advanced Management program credentials . Company performance under the compensation framework shows 2024 Compensation Adjusted EBITDA of $123.4M with a 0% STI payout for all NEOs, and company TSR in 2024 at $20.01 (value of $100 initial investment), alongside adjusted EBITDA of $161.1M in 2024 vs $204.4M in 2023; the proxy notes revenue was “consistent” vs 2023 despite industry pressures .

Past Roles

OrganizationRoleYearsStrategic impact
Valet LivingChief People Officer2017–Aug 2023 Led enterprise people strategy for residential services (chief people role)
CitigroupGlobal Head of Learning, Talent & Performance OperationsNot disclosed Led global learning/talent/performance operations
Automatic Data Processing (ADP)Division VP & GM, Recruiting TechnologyNot disclosed General manager for recruiting tech business (commercial leadership)
WellCare Health PlansHR leaderNot disclosed Human resources leadership in managed care
AramarkHR leaderNot disclosed Human resources leadership in services

External Roles

OrganizationRoleYearsNotes
Not disclosed in proxyNo external directorships or committee roles disclosed for Toledo

Fixed Compensation

Metric20232024
Base salary (annual) ($)$425,000 $425,000
Target STI (% of salary)75% 75%
Bonus paid ($)$256,250 (sign‑on $150,000 + prorated annual incentive $106,250) $0 (no STI payout)
Salary actually paid ($, SCT)$138,942 $425,000

Performance Compensation

Short‑Term Incentive (STI) – 2024

ComponentWeightingTargetActualPayoutNotes
Compensation Adjusted EBITDA75% of STI Board‑approved budget ~$123,407,000 0% of target Financial measure chosen to align with operating budget; no NEO cash awards earned
Individual goals25% of STI Role‑specific objectives Not applicable (company gate failed) 0% of target Gate tied to company financial outcome resulted in no payout

Long‑Term Incentive (LTI) – Structure and Toledo’s Grants

Grant dateInstrumentShares (target unless noted)VestingPerformance metrics
2/14/2024RSUs5,214 Vest ~1/3 on 2/14/2025, 2/14/2026, 2/14/2027 (service)
2/14/2024PRSUs13,094 target; 6,547 threshold (50%); 26,188 max (200%) Cliff vest on 2/14/2027 (service + performance) 40% EBITDA, 60% rTSR vs peers
9/5/2023RSUs12,237 (unvested at 12/31/2024) Vest ~1/3 on 9/5/2024, 9/5/2025, 9/5/2026 (service)
9/5/2023PRSUs6,547 threshold (50%) Cliff vest on 9/5/2026 (service + performance) 2023 PRSUs accelerate at 100% target upon CoC without termination

Grant date fair value for Toledo’s 2024 LTI totaled $706,685 (RSUs + PRSUs, ASC 718) .

Equity Ownership & Alignment

ItemDetail
Beneficial ownership (shares)5,557 (less than 1% of 14,349,099 shares outstanding)
Unvested RSUs (12/31/2024)12,237 (9/5/2023 grant) – market value $144,886; 5,214 (2/14/2024 grant) – market value $61,734
Unvested PRSUs (12/31/2024)6,547 threshold – payout value $77,516 (9/5/2023); 3,911 threshold – payout value $38,210 (2/14/2024)
OptionsNone outstanding for Toledo
Stock ownership guideline3x annual base salary for NEOs
Guideline compliance (12/31/2024)None of the NEOs met the holding level (including Toledo)
Hedging/pledgingCompany prohibits hedging and pledging by employees and directors
ClawbackThree‑year clawback for incentive compensation; committee can impose additional clawbacks in award agreements

Employment Terms

Scenario (as of 12/31/2024)Cash payment(s)Accelerated vesting of stock awardsHealth insurance paymentsTotal
Resignation for Good Reason$425,000 $206,620 $17,016 $648,636
Termination without Cause$425,000 $17,016 $442,016
Termination upon Change in Control (double‑trigger)$212,500 $361,653 (includes 2023 PRSUs accelerated at 100% target: $155,033) $17,016 $591,169

Additional terms:

  • Non‑compete and non‑solicit covenants of one year post‑employment; non‑disclosure and non‑disparagement included .
  • Deferred compensation plan eligibility, but no NEO participation in 2024 .
  • Life and disability insurance benefits; disability policy pays $10,000/month until age 65 upon qualifying disability .

Performance & Track Record (Company context tied to pay)

Metric20232024
Adjusted EBITDA ($)$204,439,000 $161,134,000
Compensation Adjusted EBITDA ($)$164,583,000 $123,407,000
TSR – value of initial fixed $100 investment ($)$74.33 $20.01
Peer group TSR ($)$124.34 $126.92
STI payout (Toledo)Not disclosed (received prorated annual incentive within Bonus column) 0% of target (no cash awards)
RevenueNarrative: “maintaining consistent revenue compared to 2023” (no numeric) Narrative: “maintaining consistent revenue compared to 2023” (no numeric)

Compensation Structure Analysis

  • Mix and shift: Toledo’s pay is heavily equity‑linked via RSUs/PRSUs; 2024 STI paid $0, increasing at‑risk nature tied to EBITDA and rTSR outcomes .
  • Performance metrics: 2024 PRSUs incorporate 40% EBITDA and 60% rTSR weightings; STI gated on Compensation Adjusted EBITDA aligned to Board budget .
  • Change‑in‑control economics: Double‑trigger required for most acceleration; 2023 PRSUs uniquely accelerate at 100% target upon CoC without termination (single‑trigger for that tranche) .
  • Clawback and risk controls: Robust clawback, anti‑hedging/pledging, ownership guidelines; none of the NEOs met guidelines as of 12/31/2024 .

Compensation Peer Group & Say‑on‑Pay

  • 2024 peer group (selected): Acadia Healthcare, AdaptHealth, Addus HomeCare, Amedisys, Apollo Medical, Aveanna, Brookdale, Chemed, CorVel, Encompass Health, Enhabit, Ensign, Healthcare Services Group, Kadant/Veradigm, National HealthCare, Option Care, Select Medical (17 companies) .
  • Say‑on‑Pay: 2024 advisory approval ~80% of votes cast .

Equity Ownership & Pledging (Detail)

  • Beneficial ownership: 5,557 shares; less than 1% .
  • No pledging permitted; no pledging arrangements disclosed; hedging prohibited .
  • Guideline gap: Required 3x salary; not met as of year‑end (potential alignment shortfall) .

Investment Implications

  • Pay‑for‑performance discipline: 0% STI payout in 2024 reflects strict gating on Compensation Adjusted EBITDA, a positive signal for compensation governance; future realized pay is levered to multi‑year EBITDA and rTSR outcomes via PRSUs .
  • Event‑driven sensitivity: The 2023 PRSUs’ single‑trigger CoC acceleration (100% target) introduces incremental change‑of‑control optionality; otherwise double‑trigger terms mitigate windfall risk .
  • Ownership alignment: Beneficial ownership is de minimis and below 3x salary guideline at year‑end, tempering “skin‑in‑the‑game”; however anti‑hedging/pledging and clawbacks reduce misalignment risk .
  • Vesting calendar and supply: RSUs vesting tranches through 2026/2027 and PRSU cliffs in 2026/2027 could add periodic share delivery; insider selling pressure is dependent on pre‑clearance windows and individual liquidity needs (no sales data disclosed in proxy) .
  • Retention risk: One‑year non‑compete/non‑solicit, severance of 12 months base in involuntary scenarios, and meaningful unvested equity indicate balanced retention incentives; change‑of‑control economics are moderate vs typical market .